Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone

Rajgopal Achuthan, Sandra M. Bell, Paul Roberts, Jack P. Leek, Kieran Horgan, Alexander F. Markham, Kenneth A. MacLennan, Valerie Speirs*

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Tamoxifen resistance is a serious clinical problem commonly encountered in the management of patients with breast cancer. The mechanisms leading to its development are unclear. Tamoxifen acts via multiple pathways and has diverse effects. Hence transformation from a tamoxifen-sensitive to a resistant phenotype could involve multiple genetic events. Knowledge of the genetic pathways leading to resistance may facilitate the development of novel therapeutic strategies. In this study, a variation of conventional comparative genomic hybridization (CGH) has been employed to detect genetic alterations associated with tamoxifen resistance. MCF-7, a tamoxifen-sensitive human breast cancer cells line, and its tamoxifen-resistant clone, CL-9 were used. Both cell lines showed extensive areas of concordance but consistent differences were seen with the acquisition of tamoxifen resistance. These differences included the amplification of 2p16.3∼p23.2, 2q21∼q34, 3p12.3∼p14.1, 3p22∼p26, 3q, 12q13.2∼q22, 13q12∼q14, 17q21.3∼q23, 20q11.2∼q13.1 and 21q11.2∼q21 as well as the deletion of 6p21.1, 6p23∼p25, 7q11.1∼q31, 7q35∼q36, 11p15, 11q24, 13q33, 17p, 18q12∼q21.1, 19p, 19q13.3, 22q13.1∼q13.2. These findings were supported by conventional cytogenetics and chromosome painting. The regions identified by CGH potentially harbor genes that could be important in the development of tamoxifen resistance.

Original languageEnglish
Pages (from-to)166-172
Number of pages7
JournalCancer Genetics and Cytogenetics
Volume130
Issue number2
DOIs
Publication statusPublished - 15 Oct 2001

Fingerprint

Tamoxifen
Clone Cells
Breast Neoplasms
Cell Line
Pharmaceutical Preparations
Comparative Genomic Hybridization
Chromosome Painting
Cytogenetics
Phenotype
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone. / Achuthan, Rajgopal; Bell, Sandra M.; Roberts, Paul; Leek, Jack P.; Horgan, Kieran; Markham, Alexander F.; MacLennan, Kenneth A.; Speirs, Valerie.

In: Cancer Genetics and Cytogenetics, Vol. 130, No. 2, 15.10.2001, p. 166-172.

Research output: Contribution to journalArticle

Achuthan, Rajgopal ; Bell, Sandra M. ; Roberts, Paul ; Leek, Jack P. ; Horgan, Kieran ; Markham, Alexander F. ; MacLennan, Kenneth A. ; Speirs, Valerie. / Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone. In: Cancer Genetics and Cytogenetics. 2001 ; Vol. 130, No. 2. pp. 166-172.
@article{d0a26efa9b6b4b12a13a0de964289909,
title = "Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone",
abstract = "Tamoxifen resistance is a serious clinical problem commonly encountered in the management of patients with breast cancer. The mechanisms leading to its development are unclear. Tamoxifen acts via multiple pathways and has diverse effects. Hence transformation from a tamoxifen-sensitive to a resistant phenotype could involve multiple genetic events. Knowledge of the genetic pathways leading to resistance may facilitate the development of novel therapeutic strategies. In this study, a variation of conventional comparative genomic hybridization (CGH) has been employed to detect genetic alterations associated with tamoxifen resistance. MCF-7, a tamoxifen-sensitive human breast cancer cells line, and its tamoxifen-resistant clone, CL-9 were used. Both cell lines showed extensive areas of concordance but consistent differences were seen with the acquisition of tamoxifen resistance. These differences included the amplification of 2p16.3∼p23.2, 2q21∼q34, 3p12.3∼p14.1, 3p22∼p26, 3q, 12q13.2∼q22, 13q12∼q14, 17q21.3∼q23, 20q11.2∼q13.1 and 21q11.2∼q21 as well as the deletion of 6p21.1, 6p23∼p25, 7q11.1∼q31, 7q35∼q36, 11p15, 11q24, 13q33, 17p, 18q12∼q21.1, 19p, 19q13.3, 22q13.1∼q13.2. These findings were supported by conventional cytogenetics and chromosome painting. The regions identified by CGH potentially harbor genes that could be important in the development of tamoxifen resistance.",
author = "Rajgopal Achuthan and Bell, {Sandra M.} and Paul Roberts and Leek, {Jack P.} and Kieran Horgan and Markham, {Alexander F.} and MacLennan, {Kenneth A.} and Valerie Speirs",
year = "2001",
month = "10",
day = "15",
doi = "10.1016/S0165-4608(01)00475-7",
language = "English",
volume = "130",
pages = "166--172",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone

AU - Achuthan, Rajgopal

AU - Bell, Sandra M.

AU - Roberts, Paul

AU - Leek, Jack P.

AU - Horgan, Kieran

AU - Markham, Alexander F.

AU - MacLennan, Kenneth A.

AU - Speirs, Valerie

PY - 2001/10/15

Y1 - 2001/10/15

N2 - Tamoxifen resistance is a serious clinical problem commonly encountered in the management of patients with breast cancer. The mechanisms leading to its development are unclear. Tamoxifen acts via multiple pathways and has diverse effects. Hence transformation from a tamoxifen-sensitive to a resistant phenotype could involve multiple genetic events. Knowledge of the genetic pathways leading to resistance may facilitate the development of novel therapeutic strategies. In this study, a variation of conventional comparative genomic hybridization (CGH) has been employed to detect genetic alterations associated with tamoxifen resistance. MCF-7, a tamoxifen-sensitive human breast cancer cells line, and its tamoxifen-resistant clone, CL-9 were used. Both cell lines showed extensive areas of concordance but consistent differences were seen with the acquisition of tamoxifen resistance. These differences included the amplification of 2p16.3∼p23.2, 2q21∼q34, 3p12.3∼p14.1, 3p22∼p26, 3q, 12q13.2∼q22, 13q12∼q14, 17q21.3∼q23, 20q11.2∼q13.1 and 21q11.2∼q21 as well as the deletion of 6p21.1, 6p23∼p25, 7q11.1∼q31, 7q35∼q36, 11p15, 11q24, 13q33, 17p, 18q12∼q21.1, 19p, 19q13.3, 22q13.1∼q13.2. These findings were supported by conventional cytogenetics and chromosome painting. The regions identified by CGH potentially harbor genes that could be important in the development of tamoxifen resistance.

AB - Tamoxifen resistance is a serious clinical problem commonly encountered in the management of patients with breast cancer. The mechanisms leading to its development are unclear. Tamoxifen acts via multiple pathways and has diverse effects. Hence transformation from a tamoxifen-sensitive to a resistant phenotype could involve multiple genetic events. Knowledge of the genetic pathways leading to resistance may facilitate the development of novel therapeutic strategies. In this study, a variation of conventional comparative genomic hybridization (CGH) has been employed to detect genetic alterations associated with tamoxifen resistance. MCF-7, a tamoxifen-sensitive human breast cancer cells line, and its tamoxifen-resistant clone, CL-9 were used. Both cell lines showed extensive areas of concordance but consistent differences were seen with the acquisition of tamoxifen resistance. These differences included the amplification of 2p16.3∼p23.2, 2q21∼q34, 3p12.3∼p14.1, 3p22∼p26, 3q, 12q13.2∼q22, 13q12∼q14, 17q21.3∼q23, 20q11.2∼q13.1 and 21q11.2∼q21 as well as the deletion of 6p21.1, 6p23∼p25, 7q11.1∼q31, 7q35∼q36, 11p15, 11q24, 13q33, 17p, 18q12∼q21.1, 19p, 19q13.3, 22q13.1∼q13.2. These findings were supported by conventional cytogenetics and chromosome painting. The regions identified by CGH potentially harbor genes that could be important in the development of tamoxifen resistance.

UR - http://www.scopus.com/inward/record.url?scp=0035886411&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(01)00475-7

DO - 10.1016/S0165-4608(01)00475-7

M3 - Article

VL - 130

SP - 166

EP - 172

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -